Regulation of Endogenous Glucose Production by Central KATP Channels

Meredith Hawkins

Status and phase: Enrolling; Phase 2

Conditions: Glucose Metabolism Disorders; Type 2 Diabetes Mellitus; Glucose, High Blood

Treatments: Drug: Nicotinic acid; Drug: Placebo; Drug: Diazoxide

Study type: Interventional

Funder types: Other; NIH

Identifiers

NCT03540758

R01DK069861 (U.S. NIH Grant/Contract)

2018-9039

Details and patient eligibility

About

Type 2 diabetes (T2D) affects the ability of the body to process glucose (sugar). Under fasting conditions, the liver is able to make sugar to maintain glucose levels in an important process called endogenous glucose production (EGP). Previous studies suggest that the central nervous system (CNS), including the brain, helps to regulate levels of glucose in the body by communicating with the liver. This process can be impaired in people with type 2 diabetes, and can contribute to the high level of glucose seen in these individuals.

The purpose of this study is to understand how activating control centers of the brain with a medication called diazoxide can affect how much glucose (sugar) is made by the liver. This is particularly important for people with diabetes who have very high production of glucose, which in turn can lead to diabetes complications.

Full description

In this study, the investigators will study healthy participants and participants with type 2 diabetes through a procedure called a "pancreatic clamp" study. During the clamp procedure, glucose (a sugar) and insulin (a hormone produced in the pancreas that regulates the amount of glucose in the blood) are infused with an intravenous catheter, and blood samples are collected periodically throughout the procedure to measure blood sugar levels and the levels of several hormones that are found in the body and are related to glucose metabolism. Endogenous glucose production (a measure of the body's production of sugar) will be measured in patients given diazoxide (a medication that activates potassium channels in the brain that may affect glucose production in the liver through brain-liver signaling), compared with when a placebo is given. This study will also investigate whether lowering free fatty acid levels which may help improve the body's ability to regulate glucose levels.

Aim 1: non-diabetic participants will be studied after receiving diazoxide or placebo in a randomized, single-blinded fashion to determine whether extra-pancreatic KATP channels regulate hepatic glucose fluxes in non-diabetic humans.

For Aim 1, 15 healthy, non-diabetic individuals will be studied under the following experimental conditions, in random order and in double blinded fashion:

1. normoglycemic 'pancreatic clamp' studies with administration of placebo

2. normoglycemic 'pancreatic clamp' studies with administration of diazoxide

   Aim 2: participants with type 2 diabetes will be studied after receiving diazoxide or placebo in a randomized, single-blinded fashion to establish whether central regulation of glucose production is impaired in patients with T2D

   For Aim 2, the study population will consist of 15 subjects with moderate-to-poorly controlled Type 2 Diabetes Mellitus (HbA1c 8-12%). In these studies, the effects of diazoxide on EGP under the following 2 experimental conditions will be examined, on separate occasions at least 3 weeks apart, in random order and in double blinded fashion:

3. normoglycemic 'pancreatic clamp' studies with administration of placebo

4. normoglycemic 'pancreatic clamp' studies with administration of diazoxide

Aim 3: participants with type 2 diabetes will be studied after receiving diazoxide or placebo in a randomized, single-blinded fashion after lowering their free fatty acid (FFA) levels to determine whether central regulation of glucose fluxes can be restored upon lowering FFA levels in T2D.

Chronic, moderate increases in FFA levels characteristic of T2D can increase EGP through multiple effects on hepatic glucose fluxes, which may overwhelm the effects of activating central KATP channels. 15 nondiabetic and 15 T2D subjects will be studied under baseline conditions and following nicotinic acid administration, under the following experimental conditions. EGP will be assessed in each subject on separate occasions, at least 3 weeks apart. Placebo and diazoxide will be administered in random order and in double blinded fashion. Heart rate variability may be assessed as a measure of vagal nerve activation:

1. normoglycemic (90 mg/dl) pancreatic clamp studies will be performed following nicotinic acid administration, and placebo
2. normoglycemic (90 mg/dl) pancreatic clamp studies will be performed following nicotinic acid administration, and diazoxide

Enrollment: 100 estimated patients

Sex: All

Ages: 21 to 70 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

For healthy participants:

• Age: 21-70 years old
• Body Mass Index (BMI) under 35
• Negative drug screen
• Normal Hemoglobin A1c (HbA1c) and fasting glucose
• No family history of diabetes among first degree relatives (e.g., mother, father)

For T2D participants:

• Age: 21-70 years old
• BMI under 35
• Stable and moderate-to-poor glycemic control (HbA1c: 8.0-12.0%)
• Negative drug screen
• Not suffering from a previously diagnosed proliferative retinopathy, significant diabetic renal disease or severe neuropathy (including cardiovascular and gastrointestinal autonomic dysfunction).

Exclusion criteria

• Age: Under 21 or over 70 years ol
• BMI: >35 for Type 2 Diabetes (T2D) and Non-Diabetic (ND) subjects
• Blood pressure >150/90 or <90/60 on more than one occasion
• Severe polydipsia and polyuria (in subjects with T2D). Since polydipsia and polyuria are common symptoms of T2D, the distinction "severe" denotes that the subject indicates a worsening in the symptoms and/or an experience of discomfort related to the symptoms at the time of screening and/or at the time of withdrawal from the medications
• Urine microalbumin: >300 mg/g of creatinine (in subjects with T2D)
• Uncontrolled hyperlipidemia defined as Triglycerides (TG) > 400 mg/dL and/or Total Cholesterol >300 mg/dL
• Clinically significant liver dysfunction including thrombocytopenia (platelets <100,000/uL), anemia (as below), hypoalbuminemia (<3.5 g/dL), coagulopathy (INR > 1.5), and/or liver enzymes more than 3 times the upper limit of normal
• Clinically significant kidney dysfunction, Glomerular Filtration Rate (GFR): <60 mg/dL
• Clinically significant anemia Prospective subjects with hemoglobin below the lower limit of 12 g/dl for for men and 11 g/dL for women will be assessed with history and physical exam to rule out clinically significant anemia, defined as an individual with symptoms (e.g., fatigue, weakness, shortness of breath, palpitations), signs (pallor, brittle nails etc.), or currently under treatment for anemia. In the absence of a documented hemoglobin decrease or iron deficiency, subjects will not be excluded
• Clinically significant leukocytosis or leukopenia
• Clinically significant thrombocytopenia or thrombocytosis
• Coagulopathy
• Urine drug screen positive for any of the following: amphetamines, barbiturates, benzodiazepines, cocaine, methadone, opiates, oxycodone, phencyclidine (PCP). Amphetamines, oxycodone, opiates, methadone, and benzodiazepines have been shown to affect glucose metabolism (increased glycemia, increased fasting insulin levels, delayed insulin response to food ingestion, insulin deficiency). As the drug test available in the Clinical Research Center (CRC) is a 7-drug panel, we cannot specifically choose which drugs are screened for. Additionally, in the interest of selecting patients on the basis of their reliability and dependability, we would like to exclude participants using illicit drugs. Occasional use of cannabis (once or twice per week) is not an exclusion factor. If the test is read as "indeterminate" it will be repeated at the bedside and an additional sample will be sent to the lab. Decision to enroll subject that day prior to results from lab being available will be decided on a case-by-case basis, i.e., when all previous drug testing had been negative and clinical suspicion is very low
• Urinalysis: Clinically significant abnormalities
• Clinically significant electrolyte abnormalities
• Smoking >10 cigarettes/day
• Alcohol: Men >14 drinks/week or >4 drinks/day, Women >7 drinks/week or >3 drinks/day
• History of chronic liver disease, active hepatitis infection, HIV/AIDS, chronic kidney disease (stage 3 or greater), active cancer, cardiovascular disease or other heart disease, systemic rheumatologic conditions, seizures, bleeding disorders, muscle disease
• Surgeries that involve removal of endocrine glands except for thyroidectomy (if euthyroid on thyroid hormone replacement - if such history free thyroxine (fT4) and Thyroid Stimulating Hormone (TSH) will be checked)
• Pregnant women
• Subject enrolled in another study less than one month prior to the anticipated start date of the proposed study, besides those done by our group
• Family history of premature cardiac death
• Allergies to medication administered during study
• Uncontrolled psychiatric disorders
• Any condition which in the opinion of the PI makes the subject ill suited for participation in the study

Trial design

Primary purpose: Basic Science

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Single Blind

---

100 participants in 8 patient groups, including a placebo group

Non-diabetic (Diazoxide)

Experimental group

Description:

Pancreatic clamp study will be done after giving Diazoxide (Proglycem) oral suspension to non-diabetic participants.

Treatment:

Drug: Diazoxide

Non-diabetic (Placebo)

Placebo Comparator group

Description:

Pancreatic clamp study will be done after giving a taste-matched placebo for Diazoxide (Proglycem) to non-diabetic participants.

Treatment:

Drug: Placebo

T2D (Diazoxide)

Experimental group

Description:

Pancreatic clamp study will be done after giving Diazoxide (Proglycem) oral suspension to type 2 diabetic participants.

Treatment:

Drug: Diazoxide

T2D (Placebo)

Placebo Comparator group

Description:

Pancreatic clamp study will be done after giving a taste-matched placebo for Diazoxide (Proglycem) to type 2 diabetic participants.

Treatment:

Drug: Placebo

T2D (Diazoxide + Nicotinic Acid)

Experimental group

Description:

Pancreatic clamp study will be done after giving Diazoxide (Proglycem) oral suspension to type 2 diabetic participants after lowering free fatty acids with a nicotinic acid (Niacin) infusion.

Treatment:

Drug: Diazoxide

Drug: Nicotinic acid

T2D (Nicotinic Acid + placebo for diazoxide)

Experimental group

Description:

Pancreatic clamp study will be done after lowering free fatty acids with a nicotinic acid (Niacin) infusion in type 2 diabetic participants, and after giving a taste-matched placebo for Diazoxide (Proglycem) to type 2 diabetic participants.

Treatment:

Drug: Placebo

Drug: Nicotinic acid

Non-diabetic (Diazoxide + Nicotinic Acid)

Experimental group

Description:

Pancreatic clamp study will be done after giving Diazoxide (Proglycem) oral suspension to non-diabetic participants after lowering free fatty acids with a nicotinic acid (Niacin) infusion

Experimental: Non-diabetic (Nicotinic Acid + placebo for diazoxide)

Experimental group

Description:

Pancreatic clamp study will be done after lowering free fatty acids with a nicotinic acid (Niacin) infusion in non-diabetic participants, and after giving a taste-matched placebo for Diazoxide (Proglycem) toon-diabetic participants.

Treatment:

Drug: Placebo

Drug: Nicotinic acid